Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics makes tumor-infiltrating lymphocyte (TIL) cell therapies — engineered immune cells that target solid tumors, most notably lifileucel for melanoma. The stock is up 145% over the past year on commercial momentum and is up 21% today alone.

• Revenue grew 45% YoY last quarter — real commercial-launch acceleration; ATCs (Authorized Treatment Centers) coming online is the specific growth signal, and Ochsner MD Anderson delivering Louisiana's first TIL therapy for melanoma marks continued geographic expansion.
• Operating margin was -113% and free cash flow yield is -21% — the business is still deeply cash-negative during the launch scaling; the $S-3ASR shelf registration on June 18 provides balance-sheet flexibility.
• Community models IOVA as a $10B buyout candidate — with $1.5B market cap and real commercial traction, that's a legitimate strategic-outcome framing that any big-cap oncology player could act on.
• Zero insider selling in the last 30 days — the June 18 director awards were routine, and the absence of open-market distribution at 77% of 52-week range is meaningful for a biotech that has run 145%.
• 52-week position 77th percentile with volume multiplier 3.15x — the tape is accelerating hard on today's move; the July 6 corporate presentation update ahead of healthcare conferences is likely fueling the run.

August 6 Q2 earnings is where the commercial-acceleration story either extends or corrects: revenue growth held above 40% plus specific ATC count and lifileucel prescription-growth commentary is what keeps the run alive; a modest beat with cautious guide is where today's +21% move gives back. Real cell-therapy franchise with real commercial traction and real M&A optionality — the setup rewards continued execution.